DISTRIBUTING CLINICAL SPECIMENS

Brand Owner Address Description
INTERNATIONAL GENOMICS CONSORTIUM The International Genomics Consortium 445 North 5th St., Suite 300 Phoenix AZ 85004 Distributing clinical specimens, such as blood and tissue samples, to research entities for correlative studies;medical research support services, namely, recruitment of patients and subjects for various studies;GENOMICS CONSORTIUM;Research and scientific analysis, namely, molecular and genomic sequencing and analysis comprising genomic research, bioinformatics, and diagnostic technologies to analyze complex genetic diseases; collection, processing and storage of blood and tissue samples and associated genomic data and clinical outcome information, and utilizing standardized protocols linked to a centralized molecular profiling laboratory to perform such analysis. Establishing and augmenting national and international standards for consent, tissue collection, clinical annotation, molecular analysis and representation of data; providing online medical and research information relating to biological samples obtained under standardized conditions, along with associated gene expression data and long-term patient clinical outcome data to accelerate the discovery of targets for therapy, prognosis and diagnosis; providing a research platform to allow users to facilitate transitioning of genomic discoveries from the bench to a patient's bedside to improve patient care; pharmaceutical drug development services, medical and scientific research consultation services in the field of clinical trials; medical research, collecting and analyzing clinical samples, analyzing clinical data, and DNA sequencing all in the fields of genomics, biomedicine, biosciences, and bioinformatics; computer software development services in the fields of genomics, biomedicine, biosciences, and bioinformatics;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. A method for aiding in differentiating irritable bowel syndrome from inflammatory bowel disease by determining the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, wherein an elevated level of lactoferrin substantially precludes diagnoses of IBS and other noninflammatory etiologies, and a kit usable in such method are provided. Further provided is a method for quantitating the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, to monitor gastrointestinal inflammation in persons having inflammatory bowel disease.